ReviewRegenerative therapy2025
The role of telomeres in leukemic stem cells function.
Review in Regenerative therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Associations between leukocyte telomere length and three measures of folate status: a cross-sectional analysis of NHANES 1999-2002.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The length of a telomere provides insight into the replication history of a cell. Notwithstanding the fact that the telomerase enzyme is produced by stem and progenitor cells, a considerable proportion of the documented telomere degradation takes place at these levels. Sequential transplantation remains a challenge for hematopoietic stem cells (HSCs) transfected with telomerase, despite their ability to maintain telomere length. To optimize stem cell proliferation, additional parameters must be considered [1]. In contrast, unregulated telomere depletion induced by HSCs appears to play a significant role in the pathogenesis of bone marrow failure, as demonstrated by dyskeratosis congenita. It implies that telomerase dysfunction serves as a prevalent ultimate pathogenic mechanism in this heterogeneous hereditary disorder. Although this condition is not well defined, acquired marrow failure syndromes have been linked to mutations in critical telomerase components. In light of the discovery of leukemic stem cells (LSCs) and the desire to develop anti-leukemia treatments for this population, a comprehensive understanding of the telomerase biology within this cell compartment is required. Further research must employ LSC-rich primary samples that have been selected. A more thorough understanding of the correlation between telomere length and telomerase regulation in this specific population may facilitate the creation of innovative approaches or small molecule inhibitors that specifically target the telomerase enzyme complex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.